1. Mesenchymal stromal cells in the regeneration of radiation-induced organ sequelae: will they make the difference?
- Author
-
M Benderitter, E Herrera-Reyes, and R Tamarat
- Subjects
Public Health, Environmental and Occupational Health ,Humans ,Regeneration ,Mesenchymal Stem Cells ,General Medicine ,Exosomes ,Waste Management and Disposal ,United States - Abstract
Mesenchymal stromal cells (MSCs) are a stem cell product with good safety that demonstrate significant clinical efficacy in the treatment of different pathologies, including radiation diseases (e.g. radiological burns, pelvic radiation disease). While the first results for some first human applications for the treatment of radiation disease suggest benefit, larger trials with clinically important endpoints are needed before definitive conclusions can be drawn. However, the supply and cost of MSCs remain the two main limitations for this innovative therapeutic product. Exosomes (EXOs), a stem cell product associated with MSC therapy, have shown promising efficacy and safety in humans. MSC-EXO therapeutics represent a promising next-generation approach for treating radiation diseases involving a primary (major) inflammatory component. Provided that conditions for MSC-EXO production and bio-banking are agreed in the near future, the transition to industrial production of MSC-EXOs will be possible, and this is required to initiate well-controlled clinical trials for approval by the European Medicines Agency (EMA) and US Food and Drug Administration (FDA).
- Published
- 2022